IDRx is a clinical-stage biopharmaceutical company focused on drug development. It designs precision combination therapies for cancer treatment including small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, developed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor.